These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15190232)

  • 1. Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease.
    Contin M; Martinelli P; Mochi M; Albani F; Riva R; Scaglione C; Dondi M; Fanti S; Pettinato C; Baruzzi A
    Clin Neuropharmacol; 2004; 27(3):111-5. PubMed ID: 15190232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
    Parkinson Study Group
    JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
    Ahlskog JE; Uitti RJ; O'Connor MK; Maraganore DM; Matsumoto JY; Stark KF; Turk MF; Burnett OL
    Mov Disord; 1999 Nov; 14(6):940-6. PubMed ID: 10584667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies.
    Koch W; Radau PE; Hamann C; Tatsch K
    J Nucl Med; 2005 Jul; 46(7):1109-18. PubMed ID: 16000279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.
    Innis RB; Marek KL; Sheff K; Zoghbi S; Castronuovo J; Feigin A; Seibyl JP
    Mov Disord; 1999 May; 14(3):436-42. PubMed ID: 10348466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.
    O'Brien JT; Colloby S; Fenwick J; Williams ED; Firbank M; Burn D; Aarsland D; McKeith IG
    Arch Neurol; 2004 Jun; 61(6):919-25. PubMed ID: 15210531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.
    Pöpperl G; Tatsch K; Ruzicka E; Storch A; Gasser T; Schwarz J
    J Neural Transm (Vienna); 2004 Aug; 111(8):1041-52. PubMed ID: 15254792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.
    Booij J; Tissingh G; Winogrodzka A; Boer GJ; Stoof JC; Wolters EC; van Royen EA
    Eur J Nucl Med; 1997 Jan; 24(1):68-71. PubMed ID: 9044880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
    Booij J; Speelman JD; Horstink MW; Wolters EC
    Eur J Nucl Med; 2001 Mar; 28(3):266-72. PubMed ID: 11315592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms.
    Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
    Nucl Med Commun; 2005 May; 26(5):421-6. PubMed ID: 15838424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
    Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
    J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do dopamine agonists or levodopa modify Parkinson's disease progression?
    Marek K; Jennings D; Seibyl J
    Eur J Neurol; 2002 Nov; 9 Suppl 3():15-22. PubMed ID: 12464117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.
    Walker Z; Costa DC; Walker RW; Lee L; Livingston G; Jaros E; Perry R; McKeith I; Katona CL
    Neurology; 2004 May; 62(9):1568-72. PubMed ID: 15136683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.